Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseases by Chantal Keijzer
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 20 August 2013
doi: 10.3389/fimmu.2013.00245
Treg inducing adjuvants for therapeutic vaccination against
chronic inflammatory diseases
Chantal Keijzer , Ruurd van der Zee,Willem van Eden and Femke Broere*
Immunology, Infectious Diseases and Immunology, Faculty Veterinary Medicine, University Utrecht, Utrecht, Netherlands
Edited by:
Virgil Schijns,Wageningen University,
Netherlands
Reviewed by:
Urszula Krzych,Walter Reed Army
Institute of Research, USA
Paola Massari, Boston University,
USA
*Correspondence:
Femke Broere, Immunology,
Infectious Diseases and Immunology,
University Utrecht, Faculty Veterinary
MedicineYalelaan 1, Utrecht 3584CL,
Netherlands
e-mail: f.broere@uu.nl
Many existing therapies in autoimmune diseases are based on systemic suppression
of inflammation and the observed side effects of these therapies illustrate the press-
ing need for more specific interventions. Regulatory T-cells (Treg) are pivotal controllers
of (auto-aggressive) immune responses and inflammation, and decreased Treg numbers
and/or functioning have been associated with autoimmune disease.Therefore,Treg became
frequently studied targets for more specific immunotherapy. Especially antigen-specific tar-
geting ofTreg would enable local and tailor made interventions, while obviating the negative
side effect of general immuno-suppression. Self-antigens that participate in inflammation,
irrespective of the etiology of the different autoimmune diseases, are held to be candidate
antigens for antigen-specific interventions. Rather than tolerance induction to disease incit-
ing self-antigens, which are frequently unknown, general self-antigens expressed at sites of
inflammation would allow targeting of disease independent, but inflammatory-site specific,
regulatory mechanisms. Preferably, such self-antigens should be abundantly expressed and
up-regulated at the inflammatory-site. In this perspective heat shock proteins (Hsp) have
several characteristics that make them highly attractive targets for antigen-specific Treg
inducing therapy. The development of an antigen-specific Treg inducing vaccine is a major
novel goal in the field of immunotherapy in autoimmune diseases. However, progress is
hampered not only by the lack of effective antigens, but also by the fact that other fac-
tors such as dose, route, and the presence or absence of an adjuvant, turned out to be
critical unknowns, with respect to the effective induction of Treg. In addition, the use of
a Treg inducing adjuvant might be required to achieve an effective regulatory response, in
the case of ongoing inflammation. Future goals in clinical trials will be the optimization of
natural Treg expansion (or the induction of adaptive Treg) without loss of their suppressive
function or the concomitant induction of non-regulatory T-cells. Here, we will discuss the
potential use of protein/peptide-based vaccines combined withTreg inducing adjuvants for
the development of therapeutic vaccines against chronic inflammatory conditions.
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INTRODUCTION
Autoimmune diseases are characterized by unwanted responses
to self-antigens. Current treatments are symptomatic approaches
that induce a generalized immune suppression with all the poten-
tial side effects of suppressed immune responses against infectious
diseases and cancer. A more specific targeting of the underlying
cause of disease would be of great benefit for patients. Develop-
ment of a therapeutic vaccine that can restore immune tolerance
in autoimmunity or other non-infectious chronic inflammatory
diseases might induce long-term disease remission with minimal
side effects.
In healthy individuals immunological self-tolerance is main-
tained by several mechanisms amongst others by regulatory T-cells
(Treg) (1, 2). Loss of Treg function or frequency can lead to
autoimmune diseases like type 1 diabetes (T1D) and rheuma-
toid arthritis (RA). Although several functional and phenotyp-
ical characteristics have been linked to Treg, nowadays Treg are
still mostly identified by the expression of CD25 and most Treg
express the transcription factor forkheadbox P3 (FoxP3) (3, 4).
Treg can suppress effector functions of the immune system with
a variety of mechanisms. Upon activation, Treg can produce anti-
inflammatory cytokines, consume IL-2, directly lyse effector cells,
interrupt other paths of the metabolism of effector T-cells,or inter-
act with antigen presenting cells (APCs) that subsequently down
regulate their function, thus potentially spreading the suppres-
sive activity (3). Even though many different mechanisms have
been described for their suppressive activity in different mod-
els and with potentially different Treg, all pathways have one
point in common like most other immune cells, Treg need to
be activated to become suppressive. Once activated, Treg can sup-
press immune responses also to other antigens, which is called
“bystander suppression” (5).
Many autoimmune diseases and other chronic inflammatory
disorders are characterized by either defective Treg function or
reduced frequency of Treg, both leading to a dysfunction of Treg
capacity. Targeting Treg with the appropriate antigen-adjuvant
www.frontiersin.org August 2013 | Volume 4 | Article 245 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keijzer et al. Treg inducing adjuvants
combination to enhance the Treg functionality can therefore result
in dampening of inflammation and is an attractive route to
long-term disease remission.
VACCINATION AGAINST AUTOIMMUNITY
Traditionally, vaccination is focused on the prevention of pathol-
ogy from infectious diseases by the induction of a strong protective
immune response against the pathogen. The successful implemen-
tation of numerous vaccines against infectious diseases reduced
worldwide mortality tremendously over the last decades. However,
in the meantime, in the Western World increased incidence of sev-
eral inflammatory disorders such as allergies and autoimmune
diseases, like T1D, multiple sclerosis (MS), and inflammatory
bowel disease (IBD) have been observed (6). The exact explana-
tion for this increased prevalence of non-infectious inflammatory
diseases in the Western World remains elusive. It has been sug-
gested that the increased hygiene and the subsequent reduced
number of infections encountered during childhood contribute
to the increase in atopy and autoimmune diseases as stated in the
“hygiene hypothesis” originally postulated by Strachan (6).
Originally the hygiene hypotheses focused on a disbalance
between Th1 and Th2 responses, however, recent advances in the
field of immunological homeostasis revealed an important role for
Treg in immune regulation and therefore deregulation.
Rook (7) hypothesized that some specific pathogens play an
important role in the adaptation and maturation of our immune
system during life. Absence of these so-called “old friends” might
contribute to the increased prevalence of non-infectious chronic
inflammatory conditions since immune education is incomplete.
Examples of such old friends could well be saprophytic mycobac-
teria, multiple helminths, some gut microbiota, hepatitis A virus,
Helicobacter pylori, Salmonella, Toxoplasma gondii, and ferment-
ing lactobacilli. The resolution of post-infection inflammation is
regarded to go along with the enforcement of immune homeosta-
sis and the expansion of Treg. It is a fact that the immune system
is activated by different pathogen-associated molecular patterns
(PAMPs) via pattern recognition receptors (PRRs) and these path-
ways have been exploited in the development of novel adjuvants
over the past decades. Although most adjuvant studies focused
on the enhancement of effector responses some immune stimu-
latory antigens obtained from these old friends can enhance Treg
function or frequency.
To develop an antigen-specific immunotherapeutic vaccine for
the use in patients with autoimmune disease several points have
to be considered (Figure 1).
First the nature of the antigen: in the case of autoimmunity the
exact nature of the disease-inducing antigen in most cases remains
elusive. Antigen-specific activation of Treg via the T-cell receptor
(TCR) is a prerequisite for their functionality (5), therefore we
pose the question: which (self) antigens are possible targets?
Secondly, how to induce a Treg response upon vaccination?
The majority of vaccines that induce strong adaptive responses are
injected parenterally, whereas mucosal application of self-antigens
has been shown to induce strong tolerogenic responses against the
self-antigen in several animal models of autoimmunity. Transla-
tion of so-called mucosal tolerance induction to the clinic has not
been successful. It is possible that the use of (novel) adjuvants will
FIGURE 1 |Therapeutic vaccination in autoimmune disease. A specific
vaccine must induce Treg in an antigen-specific fashion and these Treg can
subsequently suppress effector cells in an inflammatory environment.
Adjuvants and routes of administration will determine the outcome of
therapeutic vaccination.
cause a breakthrough in this area, either by favoring the induction
of Treg upon parenteral vaccination, or by enhancing the mucosal
immune response, thereby potentiating the induction of mucosal
tolerance in patients with autoimmune diseases. Thus the third
aspect that will determine the efficacy of a therapeutic vaccine
can be the nature of the adjuvant. Several adjuvants have been
described that directly induce adaptive Treg, or indirectly enhance
Treg induction via dampening inflammation. For enhancing the
specific features of mucosal vaccination we may aim to enhance
mucosally induced Treg or to additionally enhance Treg activity
of existing Treg via innate receptors. Different potential adjuvants
will be discussed in more detail below.
ANTIGEN-SPECIFIC THERAPEUTIC VACCINES; CHOICE OF
ANTIGEN
Treg need to be activated before they are functionally suppres-
sive for example via the TCR (5), this directly implies that it is
important to know the nature of the desired antigen specificity
of Treg to develop an effective vaccine. In the case of autoim-
mune diseases, autoantigens could possibly serve as targets for
such antigen-specific Treg. However, it is questionable whether
the typical autoantigens associated with specific autoimmune dis-
eases are sufficiently abundant to serve as targets, especially in cases
where the antigen is scarce due to tissue destruction. In addition,
in many cases of autoimmune disease epitope spreading plays an
important role in the etiology of disease and no single antigen
can be defined as the disease-inducing antigen. For a functional
Treg mediated suppression it is supposed that only very abundant
self-antigens may serve as targets for an effective Treg mediated
suppression (4).
Examples of abundant self-antigens are stress proteins. Stress
proteins are expressed in every cell and specifically up-regulated
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at the site of inflammatory reactions. In addition, stress proteins
are abundantly present in MHC molecules to be presented to T-
cells (8). Recently we have demonstrated that such exposed stress
protein fragments may be targeted to Treg. A peptide derived from
heat shock protein 70 (Hsp70) was found to have the capacity to
induce a very potent Treg response. Following immunization with
this Hsp70 peptide responding CD4+CD25+ spleen lymphocytes
had a high capacity to suppress disease in an experimental model
of arthritis upon adoptive transfer.
T-cells specific for self-Hsp have been demonstrated by differ-
ent groups to be beneficial in both autoinflammatory diseases and
models for chronic inflammation (9). For example the presence of
Hsp60-specific T-cells in juvenile idiopathic arthritis (JIA) patients
correlates with a beneficial disease outcome, and has been shown
immunoregulatory in RA and juvenile dermatomyositis (JDM).
In addition an Hsp-derived peptide, DnaJp1, with good binding
capacity to human HLA-DR alleles, not only induced immune
deviation in peripheral blood mononuclear cells (PBMC) from
patients after oral treatment but also reduced disease severity in
responsive patients in a phase II clinical setting (10, 11).
In an experimental skin allograft transplant model in mice,
the whole mycobacterial Hsp70 protein was found to induce graft
tolerance. Treatment of the graft tissue with Hsp70 prior to trans-
plantation delayed rejection of the graft in a Treg dependent
fashion (12).
The first known therapeutic vaccine based on an Hsp-derived
peptide is known as DiaPep277. This is an Hsp60-derived peptide
that has been shown to induce Hsp-mediated immune balance
in T1D (13, 14). This peptide-specific therapeutic approach was
extremely successful in the preclinical phase and has shown its
potential in clinical trials. Recently in phase III clinical stud-
ies where newly diagnosed patients were treated with the Hsp60
peptide for 2 years at quarterly intervals independent of insulin
treatment very promising results were obtained. Not only was
DiaPep277® -treatment safe and well tolerated. Significant reserva-
tion of C-peptide levels was observed, treated patients experienced
fewer hypoglycemic events with a significant difference in the rate
of decline in the hypoglycemic events/month. In short, Hsp60 pep-
tide treatment preserved beta-cell function and improved clinical
outcomes over 2 years in newly diagnosed T1D patients (15).
It is clear that rational development of a therapeutic vaccine
is no easy task, not only the selection of a potential vaccine anti-
gen but also the application and adjuvant combination are crucial
for the outcome of the immune response. A potentially harmless
antigen can induce a serious inflammatory T and B cell response
when administered under the wrong conditions.
WAYS TO ENHANCE TREG
ROUTE OF VACCINATION; MUCOSAL VACCINATION
Although most infections and environmental allergens are
acquired through the mucosal membranes, surprisingly, most vac-
cines are still delivered via the parenteral route because this route
of vaccination seems associated with protective antigen-specific
cellular and humoral immune responses. An alternative to conven-
tional multiple injection therapy is the mucosal route of vaccine
delivery. Compared to parenteral vaccination one major advantage
of the mucosal route of vaccination is the ability to activate both
mucosal and systemic immune responses. In addition, vaccination
at one mucosal site can induce immunity at peripheral mucosal
sites via the common mucosal immune system (16, 17). There
are various routes of mucosal vaccination of which the oral and
nasal route are most accepted and easily accessible. The immuno-
logical outcome of mucosal vaccination depends partially on the
antigen dose and the frequency of administration. A low anti-
gen dose frequently applied or a single high antigen dose can
both promote the induction of mucosal tolerance, whereas, a sin-
gle low antigen dose and frequent high antigen application can
break mucosal tolerance (18). The vaccine characteristics required
depend largely on the immune responses that are desired and
can be divided into two categories, pro-inflammatory immune
responses against invading pathogens or tumors and tolerance
induction to allergens or autoantigens. In general, the induction
of antigen-specific Treg after mucosal vaccination is the hallmark
for mucosal tolerance induction (19). The forkhead transcrip-
tion factor, FoxP3, can control both induced and natural Treg
cell development and function and these FoxP3+ Tregs can secrete
anti-inflammatory cytokines such as IL-10 or TGF-β. However,
recently, it has been reported that natural or thymus derived Treg
but not induced or peripherally derived Treg can convert into
Th17 cells after exposure to IL-6 and TGF-β (20). Besides Th1
cells, Th17 cells are major pathogenic effector T-cells in many
autoimmune diseases. On the other hand, therapeutic vaccine
induced Treg may not be in effective amounts to suppress the pool
of activated effector T-cell responses at the site of inflammation.
To overcome these problems, co-administration of Treg inducing
adjuvants might potentiate the Treg immunoregulatory function
(Figure 2).
FIGURE 2 | Distinct pathways ofTreg inducing adjuvants. The restore
immune balance in autoimmunity via vaccination depends on several
different vaccine characteristics. Therapeutic vaccination can be pursued via
a tolerogenic route, adjuvant, or suppression of effector T-cells. The perfect
vaccine will most likely contain all these aspects.
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ADJUVANTS TO ENHANCE TREG
A flurry of new therapeutic targets in autoimmune diseases has
emerged over the past years. However, in the case of autoantigens,
co-administration of an adjuvant is often required to potentiate
the immunogenicity of the antigen. In addition, adjuvants can
be used to reduce the amount of antigen and the number of
immunizations needed for protective immunity and to enhance
the delivery of antigen to mucosal sites. The type of immune
response that adjuvants elicit depends on their specific physico-
chemical characteristics. Here, we summarize the application of
several Treg inducing adjuvants in inflammatory diseases.
Cholera toxin B subunit
A first group of potent adjuvants that has been shown to enhance
the immune response after mucosal vaccination are the toxin-
based adjuvants. The enterotoxin cholera toxin (CT) from Vibrio
cholera is an example of a potent mucosal adjuvant that can induce
systemic and mucosal immune responses. However, the use of
enterotoxins as adjuvant should be avoided based on previously
reported severe adverse effects attributable to their toxic nature
(21, 22). Therefore, to improve safe use of CT, a non-toxic mutant
has been developed also known as the B subunits of CT (CTB). The
non-toxic recombinant (CTB) has been described to enhance pro-
tective immune responses against influenza virus (23, 24). How-
ever, combined with different antigens it can also enhance Treg
responses in several autoimmune disorders. For example, B cells
that were pretreated with antigen conjugated to CTB in vitro pro-
duced IL-10 and induced a B cell dependent increase in the number
of FoxP3+ Treg upon adoptive transfer, resulting in protection
against experimental autoimmune encephalomyelitis (EAE) both
prior to and after disease induction (25). In a more direct vacci-
nation approach Ploix et al. showed that oral administration of
CTB-insulin conjugates protected NOD mice from autoimmune
diabetes. The delayed onset of diabetes relied on a shift from a
Th1 to a Th2 profile in pancreatic lymph nodes and an increase in
TGF-β in the mesenteric lymph nodes (MLN) and the induction
of antigen-specific CD4+ Treg in the area of the mucosal barrier
and inflamed islets (26). A low-density lipoprotein peptide (3136–
3155) of apolipoprotein B-100 fused to CTB, when intranasally
applied, induced IL-10 producing Tr1 cells that reduced ather-
osclerosis by suppressing the activity of antigen-specific effector
T-cells (27).
Recently, ADP-ribosylation was shown to control the outcome
of the CD4+ immune response after mucosal antigen exposure
with OVA inserted into the CT-derived CTA1-DD monomeric
fusion protein that consist of the enzymatically active CT A1
subunit (CTA1) combined with two Ig-binding domains, DD, of
staphylococcal protein A (28). Here, mucosal tolerance was associ-
ated with the induction of IL-10 producing CD4+CD25−FoxP3−
Type I Treg (Tr1) cells (29).
Overall, CTB has been shown to modulate Treg. However, it
remains difficult to categorize this adjuvant, because of its ability
to break or enhance mucosal tolerance induction, which is influ-
enced by the nature of the antigen that is co-administered as well as
the dose, route,and time of application. Future research to improve
our understanding of the immunoregulatory mechanisms of CTB
is required to predict the direction of the immune response.
TLR2 ligands
During natural infections many different Toll-like receptors (TLR)
are activated and TLR mediated activation of APCs can contribute
to the induction of efficient adaptive effector responses. Different
TLR2 agonists can induce distinct cytokines pattern and signaling
in APCs and differentially skew T helper cell responses in vivo. For
example, in allergic airway inflammation, a Th2 associated inflam-
matory airway disease, the TLR2 agonist Pam3CSK4 enhanced the
production of IL-12 by DCs in vitro and in vivo therapy attenuated
established asthma in mice by shifting the antigen-specific T cell
response toward a Th1 response (30). On the other hand, after
intranasal or intraperitoneal immunization, the TLR2 ligand dia-
cylated lipopeptide FSL-1 enhanced the generation of Th2-type
IgG1 antibodies compared to the Th1-type IgG2a antibodies (31).
However, specific TLR2 activation might preferentially enhance
the induction and activation of Treg (32). The fact that TLR2
signaling can induce such a diverse range of responses is most
likely due to the fact that TLR is a transmembrane signaling pro-
tein that can form heterodimers with co-receptors such as TLR1,
TLR6, and Dectin-1 and ligand and receptor characteristics will
determine the outcome of the response. Signaling through the
TLR2/TLR1 heterodimer was shown important in the induction
of protective mucosal Th17 immune responses against infection
(33), whereas intranasal treatment with the synthetic TLR2/TLR1
agonist Pam3Cys induced an expansion of the Treg cell population
in the lungs in a mouse model of allergic asthma (34), TLR2/TLR6
receptor ligation by Yersinia pestis virulence factor LcrV and Yeast
Zymosan, a ligand for TLR2/Dectin-1 both promoted tolerogenic
dendritic cells (DCs), and the induction of Treg responses (35, 36).
Moreover, the Hsp60 peptide, Diapep277 that was shown to be
a protective peptide in the NOD diabetes mouse model by induc-
ing antigen-specific Tregs also enhanced CD4+CD25+ Treg cell
function via innate TLR2 signaling (14). In addition, a recently
conducted phase 3 multicenter trial showed that the p277 trial
had reached its primary and secondary clinical endpoints in T1D
patients (37). These data have shown the unique potential of
Treg inducing vaccination in autoimmunity and a role for TLR2
mediated immune activation.
TLR2 ligands can be applied to enhance the induction of Treg
in vivo and might be potential adjuvants in the treatment of
chronic inflammatory disease. Caution is needed when selecting
appropriate TLR2 adjuvants for Treg induction, because some
ligands for TLR2/TLR1 signaling such as Pam3Cys have been
shown to skew Treg toward a Th17 phenotype and might therefore
increase the risk of developing autoimmune disease (38). Both the
route of TLR2 adjuvant application and TLR2 receptor ligation
can significantly affect the immunological outcome of vaccina-
tion and need to be considered when selecting TLR2 ligands as
vaccine adjuvant.
Helminth-derived excretory/secretory immunoregulatory products
The “Hygiene Hypothesis” states that a lack of early child-
hood exposure to infectious agents, microorganisms, and par-
asites increases susceptibility to allergic diseases, particularly in
the developed world. Recently, the hygiene hypothesis has been
extended to also incorporate inflammatory and autoimmune dis-
eases in general (39). There is substantial evidence from animal
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models of human disease that infection with helminths can sup-
press ongoing inflammation in autoimmune diseases such as
arthritis (40), IBD (41), and EAE (42) by modulation of the
immune response.
The main disadvantage of using the whole parasite to treat
disease in general is the fact that infection with helminths can
cause severe pathology and permanent damage to the host. Stud-
ies on the mechanism of immune modulation by helminths
showed that helminth-derived excretory/secretory (ES) products
including proteins, lipids, and glycoconjugates can suppress DC
maturation (43, 44) and modulate DC functionality and induce
CD4+CD25+FoxP3+ Treg in vitro (45) and in vivo (46). For exam-
ple, a Schistosoma-derived lysophosphatidylserine molecule that
specifically activated TLR2, affected DC function and stimulated
the development of IL-10-producing Treg (47).
In addition, a single ES molecule named ES-62 derived from
the filarial nematode Acanthocheilonema viteae can suppress col-
lagen induced arthritis (CIA) by targeting IL-17 producing cells
(48). The main advantage of using helminth-derived ES products
is that a regulatory response can be induced that could dampen
chronic inflammation in the absence of infection per se, and,
increase safe application and reduce the chance of therapy associ-
ated side effects. The fact that helminth-derived ES products can
induce immunoregulatory immune responses in a variety of ani-
mal models of human disease suggests that helminth-derived ES
products act independently of the actual disease-inducing trig-
ger. Since helminth-derived ES products can induce Treg, they can
be used as potential vaccine adjuvants for successful therapeutic
intervention and might enable local activation of Treg at the site
of inflammation.
Particulate antigen delivery systems
An advantage of vaccine delivery particles compared to solu-
ble adjuvant is that the target antigen can be encapsulated by
the particle to protect it from enzymatic degradation. Vaccine
delivery particles allow large-scale production and long-term stor-
age. Moreover, particles can be easily modified to enhance their
mucoadhesiveness to epithelial cells that line the mucosal sites
or specific ligands can be incorporated that enhance tolerogenic
immune responses or ensure uptake by APCs.
Polylactic-co-glycolic-acid. Polylactic-co-glycolic-acid particles
are available as non-toxic biodegradable vaccine delivery systems
with promise for both mucosal and non-mucosal application.
Recently, PLGA particles were demonstrated to enhance retinalde-
hyde dehydrogenase enzyme activity in CD11c+ DCs that led to
and enhanced induction of CD4+FoxP3+ T-cells, in vitro, via a
retinoic acid, and TGF-β dependent mechanism (49). Observa-
tions that PLG microparticles can prolong the expression of the
major histocompatibility complex (MHC) class I and the MHC
class II molecules on the cell surface of DCs, while they do not
significantly enhance maturation of DCs (50), suggest that PLGA
particles modulate DC phenotype and function to enable them to
enhance tolerogenic immune responses.
Oral tolerance induction by a single dose of 40µg of type II
collagen (CII)-loaded PLGA particles reduced severity of CIA,
lowered T-cell responses, and resulted in a higher expression of
TGF-β mRNA in the Peyer’s patches and this implies that PLGA
particles can be applied to enhance the induction of oral tolerance
to the target antigen (51).
Nasal application of PLGA particles in mice enhanced mucosal
tolerance via the induction of CD4+FoxP3+ Treg in the nose
draining lymph nodes. Combined with an immunosuppressive
Hsp70 peptide, PLGA particles suppressed the onset of disease
and arthritis symptoms in a proteoglycan induced arthritis mouse
model (52).
The uptake of microparticles (polystyrene or PLGA) bear-
ing encephalitogenic peptides (PLP139–151 epitope) by marginal
zone macrophages that express the scavenger receptor macrophage
receptor with collagenous structure (MARCO) ameliorated EAE
by the activation of Treg that inactivated pathogenic effector T-cell
responses (53).
These studies show the potential of PLGA particles to be applied
as enhancers of T-cell mediated tolerance in autoimmunity.
Liposomes. Next to PLGA particles also other particulate systems
might aid in the induction of tolerance. Liposomes are vesicles
composed of one or more phospholipid membranes that can
deliver a broad range of molecules (54). Liposomes can be mixed,
coated, or loaded with a variety of antigen including protein, pep-
tide, DNA-complexes, and even whole inactivated virus vaccine
and such tailor made liposomes can be utilized to steer the immune
response after vaccination. Liposomes loaded with OVA and NF-
κB inhibitor induced antigen-specific FoxP3+ Treg and methylated
BSA and NF-κB inhibitor loaded liposome treatment reduced the
severity of antigen-induced arthritis in mice (55). Next to NF-kB
inhibitors other immunosuppressants can be encapsulated, such
as rapamycin analogs (see below). Moreover, addition of specific
targeting molecules to enhance antigen uptake by tolerogenic DCs
(e.g., via DEC205) might also enhance the tolerogenic capacity of
liposomes (56).
In conclusion, liposomes can be used as antigen delivery sys-
tems in a variety of diseases and due to the fact that also other
immune modulating compounds can be co-packaged liposome
content can be adjusted to induce Tregs.
IMMUNOSUPPRESSANT DRUGS
When considering a therapeutic vaccination in the case of autoim-
mune disease in most cases such a novel antigen-specific thera-
peutic approach will be applied in combination with a form of
general immune suppression as most current therapies comprise.
However to restore immune balance the immunosuppressant drug
might be considered potential Treg inducing adjuvants A sug-
gested common mechanism whereby immunosuppressant’s such
as dexamethasone, vitamin D3 analogs, and rapamycin analogs
can enhance Treg induction is via the induction of immature
or tolerogenic DCs that express lower levels of MHC class II
and co-stimulatory molecules (CD40, CD80, and CD86) and do
not produce pro-inflammatory cytokines and promote Treg dif-
ferentiation upon antigen presentation (57). Here, we describe
some immunosuppressant drugs, that can potentially act as Treg
inducing adjuvant.
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Rapamycin and analogs
Rapamycin and its analogs everolimus, fingolimod, and tacrolimus
are immunosuppressive drugs and target mTOR. Rapamycin
inhibits the protein kinase activity of mTOR that promotes cell
growth and metabolism (58). In the clinic, rapamycin is often
used as a drug to suppress CD4+ “memory” T-cell responses
to prevent allograft rejection (59). However, rapamycin can
also efficiently convert naïve T-cells into adaptive Treg and re-
establish long-term immune self-tolerance in a variety of autoim-
mune diseases. Rapamycin promoted the expansion of functional
CD4+CD25+FOXP3+ Treg in both healthy individuals and in
T1D patients (60, 61). Moreover, rapamycin monotherapy already
affected human CD4+CD25+FOXP3+ Treg function directly
in vivo as nTreg isolated from T1D patients under rapamycin
treatment had an increased capability to suppress proliferation
of CD4+CD25− effector T-cells compared with that before treat-
ment, without inducing alterations in the frequency of circulating
nTreg and proliferation and cytokine production (62).
In an animal model for EAE rapamycin was found to increase
the percentage of CD4+CD25+FoxP3+ Treg and reduced the
clinical signs (63–65).
Most studies directly studied the immunosuppressive effects of
rapamycin on the heterologous Treg population, however, more
recently rapamycin has been shown to be a functional adjuvant
that may induce and expand antigen-specific Treg. Wu et al.
showed that mice immunized with OVA with either rapamycin
or fingolimod had significantly higher percentage and cell num-
ber of antigen-specific CD4+CD25+FoxP3+ Treg compared to
mice that received protein immunization alone. These data show
the potential of rapamycin and its analog fingolimod as potential
Treg inducing adjuvants. This effect could solely be attributed to
the immunosuppressive function of rapamycin and fingolimod
as mice immunized with OVA and treated with other immuno-
suppressive drugs such as cyclosporin A, mycophenolate mofetil,
leflunomide, or cyclophosphamide showed decreased levels of
OVA-specific CD4+CD25+FoxP3+ Treg in the draining lymph
nodes and spleen (66).
The rapamycin analog everolimus can convert naïve T-cells
into FoxP3+ Treg in vivo by interfering with T-cell costimula-
tion and by reducing proliferation. A combination therapy of
everolimus and IL-2/IL-2ab complexes could even further enhance
the number of IL-10 secreting anergic CD25+FoxP3− T-cells
in vivo, most likely by enhancing expansion of induced Treg in
an IL-2 dependent fashion (67). For tacrolimus it was shown
that the immunomodulatory action functioned via blocking of
DC maturation after it enhanced the number of tolerogenic IL-
10 expressing CD11c+ DCs. A combination of the p2MOG35
and the adjuvant tacrolimus enhanced the induction of antigen-
specific Treg that infiltrated the spinal cord and protected mice
from EAE. Protection coincided with decreased expression of
IFN-γ and reduced numbers of Th17 cells (68).Although the
exact mode of action might differ between rapamycin ramaycin
and the different analogs the studies described show that a
combination of the immunosuppressive drugs can be used as
an immune modulating a immune modulating adjuvant for
therapeutic vaccines.
Vitamin D3 analogs
Another potential adjuvant that induces tolerogenic DCs is 1α,25-
Dihydroxyvitamin D3 (1,25(OH)2D3). The potent inhibition
of NF-κB expression leads to tolerogenic DCs with increased
potential to induce Treg. A combination of antigen-specific
immunotherapy with 1,25(OH)2D3 in a murine model for asthma
enhanced the suppressive effect of therapy in an IL-10 and TGF-
β dependent fashion (69). Moreover Treg inducing capacity of
vitamin D3 analogs has been shown after topical application of
calcipotriol. Calcipotriol treatment reduced Langerhans cell mat-
uration thereby promoting the expansion of antigen-specific Treg
and reduced antigen-specific priming of effector CD8+ T-cells in
an OVA-induced model of skin hypersensitivity (70). The data
showed that interfering with DC maturation and induction of
tolerogenic DCs favors the induction of Treg upon antigen pre-
sentation, however, this is not unique to vitamin D3 analogs and
compounds with a comparable mode of action might also be
potent adjuvants for the induction of Treg.
Retinoic acid
The vitamin A metabolite retinoic acid plays a role in the induc-
tion of mucosal tolerance. In more detail, retinoic acid produced by
mucosal DCs acts on naïve T- and B-lymphocytes and induces the
expression of mucosal homing receptorsα4β7-integrin and CCR9.
The function of retinoic acid depends largely on the microenvi-
ronment especially the cytokine milieu. For example, retinoic acid
in the presence of TGF-β mediates the conversion of naïve T-
cells into FoxP3 expressing Treg, while retinoic acid alone at high
concentration inhibits the differentiation of Th17 cells (71, 72).
In mice with CIA all-trans retinoic acid (ATRA) directly
increased the percentages of total FoxP3+ Treg cells in the spleens
and reduced the expression of IL-17 in the arthritic joints and Th17
cells in the spleens of ATRA treated mice. ATRA treatment down-
regulated the expression of RANKL a key osteoclastogenic mol-
ecule expressed in CD4+ T-cells and fibroblast-like synoviocytes
and osteoclast formation in arthritis joints was reduced (73).
All-trans retinoic acid treatment inhibited diabetes in NOD
mice with established insulitis by the expansion of Treg cells that
suppressed IFN-γ-producing CD4+ and CD8+ T-cells, without
affecting Th17 cells or IL-4 producing cells. In addition, deple-
tion of CD4+CD25+ Treg impaired the inhibitory effect of ATRA
on islet-infiltrating CD8+ T-cells and blocked its protective effect
on diabetes (74). Moreover, when CD8+ T-cells were exposed to
ATRA and TGF-β these cells differentiated into CD8+Foxp3+ Treg
ex vivo. These CD8+ antigen-specific Treg suppressed proliferation
of diabetogenic T-cells isolated from NOD mice in vitro and could
prevent the onset of diabetes in NOD-CSID mice in vivo (75).
Most studies on the role of retinoic acid describe the induction
of heterologous Treg, however, it can be hypothesized that when
combined with a specific antigen in a vaccine, antigen-specific Treg
will be induced in vivo.
To summarize, different immunosuppressive drugs can pro-
mote the generation of Treg both in vitro and in vivo. Since
immune suppressive treatment is the current therapy in sev-
eral autoimmune diseases to suppress effector responses, it can
be speculated that these drugs can be effective as Treg inducing
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adjuvant as part of a therapeutic vaccine for chronic inflammatory
disorders.
CHEMICAL COMPOUNDS
In general, most adjuvants currently clinically applied in vaccines
are chemicals such as MF59, Aluminum hydroxide (Alum), and
adjuvant systems including AS04, which is a combination of alum
and the TLR4 agonist MPL. These adjuvants are mostly described
for their induction of effector responses and protective immunity
in infectious diseases such as influenza (76) or anti-cancer immu-
nity (77). However, in some cases also regulatory actions attributed
to these adjuvants as described below.
Alum
Alum is the most widely used vaccine adjuvant, but its mechanism
of action remains largely unknown, therefore it is not surpris-
ing that even immunomodulatory actions have been described
for a well-known adjuvant as alum. Hjorth et al. recently stud-
ied the immunomodulatory effect of alum-formulated glutamic
acid decarboxylase 65 (GAD-Alum) in autoimmune T1D patients.
PBMCs were isolated from blood samples of GAD-alum injected
patients, and restimulated by GAD65. The treatment induced
GAD65-specific CD4+CD25highFOXP3+ cells in recent-onset
T1D children and adolescents (78). In addition, in alum-treated
ApoE−/− mice the protective effect of alum relied on an increased
percentage of CD4+CD25+FoxP3+ Treg most likely activated by
tolerogenic APCs that presented oxidized LDL antigens, while hav-
ing a down-regulated expression of CD28 and ICOS activation
markers (79). These studies show that an adjuvant that has been
widely used to induce effector responses can induce Treg under
specific circumstances. However, the exact requirements for alum
to function as a Treg inducing adjuvant are unclear, more research
is needed to unravel this.
Incomplete Freund’s Adjuvant
Another adjuvant that has been used widely to induce effec-
tor responses in different animal models at least is incomplete
Freund’s adjuvant (IFA). NOD mice with prediabetic stages of
diabetes can be protected from diabetes after immunization with
the 9–23 amino acid region of the insulin B chain (B:9–23) in
IFA. A single B:9–23/IFA immunization increased Treg num-
bers that required IFN-γ and IL-10. CD4+CD25+ and to a
lesser extent IFN-γ-producing cells from mice protected by B:9–
23/IFA induced tolerance upon transfer into new NOD animals
and protection from disease coincided with reduced numbers of
diabetogenic NRP-V7+CD8+ T-cells (80).
In this setup both the antigen and the prophylactic timing of the
vaccination are likely to contribute to the protective effect. How-
ever, whether IFA can also function as a Treg inducing adjuvant in
a therapeutic setting needs to be addressed in future studies.
MONOCLONAL ANTIBODY THERAPY
Monoclonal antibodies (mAb) that negatively regulate T-cell
function can be used as immunosuppressant agents. Antibod-
ies that target CD3 molecules modulate the CD3/TCR complex
and are potent immunosuppressive agents. Since the C-terminal
domain of the heavy immunoglobulin chain (Fc) of the anti-
CD3 antibodies can interact with Fc receptors or C1q molecules,
anti-CD3-specific antibodies exhibit toxic mitogenic properties
(81). However, non-mitogenic antibodies are available also known
as non-Fc-binding anti-CD3 F(ab′)2 that can restore self-tolerance
in non-diabetic (NOD) mice via the induction of TGF-β produc-
ing CD4+CD25+ Treg cells (82). Combination therapy of systemic
anti-CD3 and intranasal human proinsulin II B24-C36 peptide
induced antigen-specific Treg that reversed recent-onset diabetes
in mice. In vivo expanded Treg that produced IL-10, TGF-β,
and IL-4 suppressed auto-aggressive CD8+ T-cell responses upon
adoptive transfer to recent-onset diabetic recipient mice (83).
In LDLR−/− C57CL/6 mice, anti-CD3 antibody treatment
reduced plaque development when administered before a high-
cholesterol diet and markedly decreased lesion progression in mice
with already established atherosclerosis. The anti-atherosclerotic
effect was associated with increased TGF-β secretion by ex vivo
ConA stimulated lymph node cells and FoxP3 expression in
spleens of anti-CD3 treated mice (84). Cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) is a negative regulator of T-
cell function. CTLA-4-Ig (a fusion protein composed of the
Fc region of immunoglobulin IgG1 fused to the extracellular
domain of CTLA-4) also known as Abatacept, is an immuno-
suppressive agent effective in the treatment of RA that blocks
the B7/CD28 co-stimulatory interaction and inhibits effector
T-cell proliferation. In vitro, CTLA-4-Ig treatment in combi-
nation with TCR ligation converted naive CD4+CD25- T-cells
into CD4+CD25+FoxP3+ Treg in an APC-dependent but TGF-
β signaling independent manner. In vivo, systemic administration
of CTLA-4-Ig increases the percentage of CD4+CD25hiFoxp3+
cells within mixed lymphocyte reaction-induced murine lymph
nodes (85).
CTLA-4-Ig treatment modified CD11c+ DCs from CIA mice
into tolerogenic DCs that upon adoptive transfer to recipient mice
with induced CIA increased the CD4+CD25+FoxP3+ Treg pop-
ulation in joint and spleen and suppressed IL-17+CD4+ T-cells
(86). Anti-CTLA-4 mAb treatment induced an increased pro-
liferation rate of IL-10 producing ICOShighFoxP3+CD4+T-cells
in the MLN and colon, inhibited Th1 memory responses, and
ameliorated TNBS-induced colitis in mice (87).
To summarize, monoclonal antibodies can be used to negatively
regulate T-cell effector responses directly or via the induction of
tolerogenic DCs and Treg.
COMBINATION THERAPY
Chronic inflammatory diseases in general are complex disorders
where multiplicities of pathogenic elements have a combined con-
tribution to the disease process. Since several immune functions,
rather than individual pathways should perhaps be targeted, com-
bination therapies might offer new opportunities to overcome
obstacles seen for single approach therapies. The aim of com-
bination therapy would be to dampen pro-inflammatory effector
responses at the site of inflammation with a disease modifying
biological agent followed by the application of a disease-specific
therapeutic agent to increase antigen-specific Treg responses.
Roord et al. showed that in rats with adjuvant arthritis, the com-
bination of an arthritogenic peptide (Hsp60 p. 180–188) with
one-third of the regular dose of etanercept led to significant dis-
ease improvement and regulatory immune deviation (88). Thus,
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combination therapy offers several advantages over monotherapy,
besides increasing the suppressive activity of disease-specific Treg,
it most likely will also be effective with a lower dose usage of the
immunosuppressive agent thereby reducing the risk of developing
therapy-related adverse side effects.
CONCLUSION
Here, we have reviewed a variety of adjuvants used to induce
Treg that have great potential for future vaccine development in
chronic inflammatory autoimmune diseases. Autoimmune dis-
eases are characterized by unwanted responses to self-antigens
that are often unknown. This complicates the development of an
antigen-specific Treg inducing therapeutic vaccine. Alternatively,
Hsp are abundantly up-regulated under conditions of stress, and in
that respect, Hsp protein/peptide might induce Hsp-specific Treg
that can suppress antigen-specific effector cell responses at the site
of inflammation. These immunoregulatory antigens most likely
need to be combined with a Treg inducing adjuvant to achieve
an effective regulatory response, in the case of ongoing inflam-
mation. Thus, the ideal therapeutic vaccine for chronic inflam-
matory diseases will require a combination of several approaches,
including “mucosal” application of an immunoregulatory anti-
gen, the use of a Treg inducing adjuvant and the ability to suppress
antigen-specific effector cells.
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